Gyre Therapeutics Inc (GYRE) Stock Price, Quote & News

Company Profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 567 7770

Website: www.gyretx.com

Address:

12770 High Bluff Drive, Suite 150, San Diego, United States

FightingNerds May. 7 at 5:21 PM

$GYRE $LTBR $WKEY $SBET spark

0 · Reply

prismmarketview May. 4 at 3:33 PM

$GYRE Gyre Therapeutics Closes Cullgen Acquisition, Forging U.S.- and China-Based Integrated Biopharmaceutical Powerhouse https://prismmarketview.com/gyre-therapeutics-closes-cullgen-acquisition-forging-u-s-and-china-based-integrated-biopharmaceutical-powerhouse/

0 · Reply

SuperGreenToday Apr. 28 at 11:03 AM

$GYRE Share Price: $7.65 Contract Selected: Oct 16, 2026 $7.5 Calls Buy Zone: $1.53 – $1.89 Target Zone: $2.61 – $3.18 Potential Upside: 61% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantum_Capital_LLC Apr. 22 at 6:58 PM

$ATAI $GYRE $IVVD $KZIA $UNCY ATAI made a move, now KZIA is making a move. UNCY is doing alright but GYRE and IVVD seem to have reversed course. GL to all.

0 · Reply

Biotech_Pharma_Investor Apr. 21 at 7:41 AM

$PRLD next catalyst will be DAC partnership. Even though pipeline is early each asset has best-in-class potential in large TAMs RA funding (following Incyte partnership) further validates the potential. Recent expansion of $CCCC partnership with Roche also validates DAC interest. Not many public small/mid-cap DAC players $PRLD $CCCC $NRIX $GYRE (other?)

1 · Reply

Quantum_Capital_LLC Apr. 16 at 9:52 PM

$ATAI $GYRE $IVVD $KZIA $UNCY ATAI vol today 16.68M with avg 4.12M. KZIA vol today 282K with avg vol 171K. Accumulation happening. What I look for with small caps; someone knows something.

0 · Reply

Quantum_Capital_LLC Apr. 16 at 1:13 AM

$ATAI $GYRE $IVVD $KZIA $UNCY normally I deal only with Mega/Large Caps but occasionally I find charts that have good short term technical indicators for Swing Trades (4, 8, 12 weeks). Theses are some I found recently with good potential.

0 · Reply

notreload_ai Mar. 17 at 5:41 PM

China’s NMPA has granted priority review to $GYRE NDA for Hydronidone (F351) for chronic hepatitis B liver fibrosis. https://notreload.xyz/china-nmpa-fast-tracks-gyre-therapeutics-hydronidone-f351/

0 · Reply

Channelchek Mar. 13 at 1:54 PM

Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – 4Q25 Report Meets Expectations As A Transition Year Begins 4Q25 Revenues Showed Modest Increase. Gyre reported a 4Q loss of $1.7 million or $(0.02) per share and profit of $5.0 million or $0.06 per basic share and $0.02 per fully diluted share. Revenues of $116.6 million increased 10.2% over the $105.8 million in FY2024. Read full report here: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-4q25-report-meets-expectations-as-a-transition-year-begins?utm_source=stocktwits&utm_medium=social&utm_campaign=research

0 · Reply

Omgyre Mar. 5 at 3:23 PM

$GYRE At the Center for Drug Evaluation (CDE) in China, there has been a development in which F351 has been officially announced (listed) as a candidate for “Priority Review.”

0 · Reply

Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year

May 7, 2026, 6:00 AM EDT - 11 hours ago

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

May 4, 2026, 8:47 AM EDT - 3 days ago

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

2026-03-17T11:20:22.000Z - 7 weeks ago

Gyre Therapeutics’ liver fibrosis candidate granted priority review in China

Mar 17, 2026, 7:00 AM EDT - 7 weeks ago

Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

2026-03-12T10:06:25.000Z - 2 months ago

Gyre Therapeutics reports Q4 EPS (2c), consensus 1c

2026-03-12T10:05:41.000Z - 2 months ago

Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M

Mar 12, 2026, 6:00 AM EDT - 2 months ago

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-03-02T13:35:43.000Z - 2 months ago

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

PULM

2026-03-02T13:29:15.000Z - 2 months ago

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

PULM

2026-03-02T13:23:53.000Z - 2 months ago

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

PULM

Mar 2, 2026, 8:00 AM EST - 2 months ago

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

2026-01-05T12:15:19.000Z - 4 months ago

Gyre Therapeutics announces alignment with China’s CDE on hydronidone

Jan 5, 2026, 7:00 AM EST - 4 months ago

Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

2025-11-07T11:21:47.000Z - 6 months ago

Gyre Therapeutics cuts FY25 revenue view to $115M-$118M from $118M-$128M

2025-11-07T11:15:13.000Z - 6 months ago

Gyre Therapeutics reports Q3 EPS 3c, consensus (2c)

Nov 7, 2025, 6:00 AM EST - 6 months ago

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

2025-10-15T11:05:18.000Z - 7 months ago

Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules

Oct 15, 2025, 7:00 AM EDT - 7 months ago

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

2025-10-10T09:25:13.000Z - 7 months ago

Gyre Therapeutics initiated with a Buy at Jefferies

Sep 10, 2025, 12:30 PM EDT - 8 months ago

Gyre Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:05 PM EDT - 8 months ago

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-26T11:20:35.000Z - 9 months ago

Gyre Therapeutics initiated with a Buy at H.C. Wainwright

2025-08-22T11:05:39.000Z - 9 months ago

Gyre Therapeutics appoints Dan Weng to board of directors

Aug 22, 2025, 7:00 AM EDT - 9 months ago

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

2025-08-11T20:05:19.000Z - 9 months ago

Gyre Therapeutics CEO Han Ying steps down

Aug 11, 2025, 4:01 PM EDT - 9 months ago

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

2025-06-10T11:10:17.000Z - 11 months ago

Gyre Therapeutics announces first doing in Phase 1 trial of F230

Jun 10, 2025, 7:00 AM EDT - 11 months ago

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

May 29, 2025, 4:01 PM EDT - 1 year ago

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

2025-05-23T04:00:34.000Z - 1 year ago

Gyre Therapeutics 2.22M share Spot Secondary priced at $9.00

May 22, 2025, 8:57 PM EDT - 1 year ago

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

May 22, 2025, 4:02 PM EDT - 1 year ago

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

May 22, 2025, 4:01 PM EDT - 1 year ago

Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

May 9, 2025, 6:00 AM EDT - 1 year ago

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Mar 17, 2025, 4:15 PM EDT - 1 year ago

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Nov 13, 2024, 6:00 AM EST - 1 year ago

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Oct 7, 2024, 2:30 PM EDT - 1 year ago

Gyre Therapeutics Transcript: H.C. Wainwright 8th Annual MASH Virtual Conference

Oct 1, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Gyre Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 15, 2024, 10:45 AM EDT - 1 year ago

Gyre Therapeutics Transcript: Sidoti Micro-Cap Virtual Conference

Aug 13, 2024, 6:00 AM EDT - 1 year ago

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Jul 2, 2024, 4:05 PM EDT - 2 years ago

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Jun 18, 2024, 4:05 PM EDT - 2 years ago

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

May 30, 2024, 4:05 PM EDT - 2 years ago

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

May 28, 2024, 4:05 PM EDT - 2 years ago

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

May 9, 2024, 4:10 PM EDT - 2 years ago

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Mar 26, 2024, 6:00 AM EDT - 2 years ago

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Dec 15, 2023, 9:04 AM EST - 2 years ago

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Nov 13, 2023, 7:00 AM EST - 2 years ago

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

FightingNerds May. 7 at 5:21 PM

$GYRE $LTBR $WKEY $SBET spark

0 · Reply

prismmarketview May. 4 at 3:33 PM

0 · Reply

SuperGreenToday Apr. 28 at 11:03 AM

0 · Reply

Quantum_Capital_LLC Apr. 22 at 6:58 PM

$ATAI $GYRE $IVVD $KZIA $UNCY ATAI made a move, now KZIA is making a move. UNCY is doing alright but GYRE and IVVD seem to have reversed course. GL to all.

0 · Reply

Biotech_Pharma_Investor Apr. 21 at 7:41 AM

1 · Reply

Quantum_Capital_LLC Apr. 16 at 9:52 PM

$ATAI $GYRE $IVVD $KZIA $UNCY ATAI vol today 16.68M with avg 4.12M. KZIA vol today 282K with avg vol 171K. Accumulation happening. What I look for with small caps; someone knows something.

0 · Reply

Quantum_Capital_LLC Apr. 16 at 1:13 AM

0 · Reply

notreload_ai Mar. 17 at 5:41 PM

China’s NMPA has granted priority review to $GYRE NDA for Hydronidone (F351) for chronic hepatitis B liver fibrosis. https://notreload.xyz/china-nmpa-fast-tracks-gyre-therapeutics-hydronidone-f351/

0 · Reply

Channelchek Mar. 13 at 1:54 PM

0 · Reply

Omgyre Mar. 5 at 3:23 PM

$GYRE At the Center for Drug Evaluation (CDE) in China, there has been a development in which F351 has been officially announced (listed) as a candidate for “Priority Review.”

0 · Reply

Channelchek Mar. 3 at 2:05 PM

Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Cullgen Acquisition Adds New Platform To Build Long-Term Pipeline Gyre To Acquire Cullgen. Gyre Therapeutics announced the acquisiton of Cullgen, a privately-held company developing targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies. The all-stock transaction valued Cullgen at approximately $300 million. We believe this acquisition adds a novel technology platform to the mid-term to long-term product pipeline. Read full report here: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-cullgen-acquisition-adds-new-platform-to-build-long-term-pipeline

0 · Reply

StocktwitsNews Mar. 2 at 7:15 PM

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead $PULM $GYRE https://stocktwits.com/news/equity/markets/pulmatrix-shares-dive-as-privately-held-pharma-company-chooses-to-merge-with-gyre-therapeutics-instead/cZd3KbURI2h

0 · Reply

madan_shatri Mar. 2 at 3:45 PM

$PULM So one of the subsidiaries of GNI Group, $GYRE has bought its own sister concern Cullen. Although different business entities but both GYRE & Cullgen are subsidiaries of GNI Group. So, all ended up in one family

1 · Reply

notreload_ai Mar. 2 at 2:55 PM

$GYRE , $PULM ... Gyre Therapeutics agrees to acquire Cullgen in $300M all-stock deal, gaining TPD/DAC platform for oncology, pain, and inflammatory diseases. Deal to close Q2 2026 after Cullgen ends Pulmatrix merger. https://notreload.xyz/gyre-therapeutics-strikes-300m-all-stock-deal-to-acquire-cullgen/

1 · Reply

BillionerOfKing Feb. 26 at 11:26 PM

$GYRE Current Stock Price: $8.53 Contracts to trade: $7.5 GYRE Apr 17 2026 Call Entry: $2.08 Exit: $3.22 ROI: 55% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

jade100 Feb. 23 at 7:50 AM

$GYRE $MDGL https://baijiahao.baidu.com/s?id=1856906520804004398&wfr=spider&for=pc There is a chance for it to become ten times larger compared to Madrigal’s market capitalization.

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:36 AM

$GYRE RSI: 54.15, MACD: 0.1326 Vol: 0.22, MA20: 8.00, MA50: 7.72 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

VolatilityControl Feb. 18 at 4:40 PM

$GYRE Gyre Therapeutics operates biopharma assets in China. Regulatory clarity and trial execution drive valuation. Policy risk remains.

0 · Reply

BillionerOfKing Feb. 11 at 2:33 PM

$GYRE Current Stock Price: $8.15 Contracts to trade: $7.5 GYRE Feb 20 2026 Call Entry: $0.59 Exit: $1.14 ROI: 94% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

TendieTyrant Feb. 4 at 3:42 PM

$GYRE is a biotech company; without specifics, it is a high-risk investment dependent on the success of its preclinical or clinical pipeline.

0 · Reply

Market Cap	754.61M
Revenue (ttm)	116.59M
Net Income (ttm)	5.03M
EPS (ttm)	N/A
PE Ratio	72.00
Forward PE	N/A
Profit Margin	4.31%
Debt to Equity Ratio	0.00

Volume	167,488
Avg Vol	102,910
Day's Range	N/A - N/A
Shares Out	96.99M
Stochastic %K	94%
Beta	2.03
Analysts	Sell
Price Target	$18.67